Cargando…
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response
PURPOSE: Some chemotherapeutics have been shown to induce both the release of damage-associated molecular patterns (DAMPs) and the production of type I interferon (IFN-I), leading to immunogenic cell death (ICD). However, the standard chemotherapy drug for glioma, temozolomide (TMZ), cannot induce I...
Autores principales: | Yin, Peidi, Li, Huifeng, Ke, Chao, Cao, Guangxu, Xin, Xiaoqian, Hu, Junjiao, Cai, Xiangran, Li, Lingfeng, Liu, Xiaowen, Du, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065718/ https://www.ncbi.nlm.nih.gov/pubmed/32189965 http://dx.doi.org/10.2147/IJN.S240551 |
Ejemplares similares
-
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response [Corrigendum]
Publicado: (2020) -
Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
por: Hu, Junjiao, et al.
Publicado: (2022) -
Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders
por: Islam, Salman Ul, et al.
Publicado: (2020) -
Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer’s Disease
por: Fihurka, Oksana, et al.
Publicado: (2023) -
METTL3 promotes cell cycle progression via m(6)A/YTHDF1-dependent regulation of CDC25B translation
por: Li, Huifeng, et al.
Publicado: (2022)